Checkpoint Inhibitors Market Report 2023

Checkpoint Inhibitors Global Market Report 2023 – By Drug (PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4, Chimeric Antigen Receptor T-cell, Other Drugs), By Application (Lung Cancer, Renal Cancer, Blood Cancer, Bladder Cancer, Melanoma, Other Applications), By End-Users (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies) – Market Size, Trends, And Global Forecast 2023-2032

Starting Price : $5000.00 | Pages : 250 | Published : January 2023 | Delivery Time: 2-3 business days | Format :

Need assistance or more information before the purchase?

Enquire Before Buying
Checkpoint Inhibitors Market

Proud Members Of

Checkpoint inhibitors refer to an immunotherapy strategy that prevents immune checkpoint proteins from forming interactions with other proteins. Because of this, the T cells are able to destroy cancer cells because the "off" signal is not sent. One such medication works against the checkpoint protein CTLA-4.

The main types of drugs in checkpoint inhibitors are PD-1 inhibitors, PD-L1 inhibitors, CTLA-4, chimeric antigen receptor T-cells, and others. PD-1 inhibitors and PD-L1 inhibitors are anticancer checkpoint inhibitors that impede the action of the immune checkpoint proteins PD-1 and PDL1 on the cell surface. It is used in lung cancer, renal cancer, blood cancer, bladder cancer, melanoma, and others, and is implemented in various sectors such as hospital pharmacies, retail pharmacies, and online pharmacies.

The global checkpoint inhibitors market is segmented –

1) By Drug: PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4, Chimeric Antigen Receptor T-Cells, Other Drugs

2) By Application: Lung Cancer, Renal Cancer, Blood Cancer, Bladder Cancer, Melanoma, Other Applications

3) By End-Users: Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies

The global checkpoint inhibitors market size grew from $23.93 billion in 2022 to $27.83 billion in 2023 at a compound annual growth rate (CAGR) of 16.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The size of the global checkpoint inhibitors market is expected to grow from $49.12 billion in 2027 at a CAGR of 15.3%.

The rise in the number of cancer cases across the globe is likely to contribute to the growth of the checkpoint inhibitors market during the forecast period. For instance, in January 2022, according to the American Cancer Society, there will likely be 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in the US, or roughly 1,670 fatalities every day. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43 percent of all new cancer cases. Checkpoint inhibitors targeting the checkpoints are very helpful as cancer therapies. Therefore, the rise in cancer incidence rates globally is anticipated to boost for checkpoint inhibitors market demand.

Major players in the checkpoint inhibitors market report are AstraZeneca PLC., Bristol-Myers Squibb Company, Merck & Co., Inc., Roche Holding AG, Pfizer, Incyte Corporation, Novartis AG, and NewLink Genetics Corporation.

The high cost of checkpoint inhibitor cancer treatment is expected to limit the checkpoint inhibitor market. The pressure to contain costs and demonstrate value is widespread. Political uncertainty and persistent economic stress in numerous countries are calling into question the sustainability of public health care funding. In less wealthy countries, the lack of cost-effective therapies for cancer has influenced the health conditions of the population and has led to a low-average life expectancy. For instance, the cost of a course of intravenous checkpoint inhibitor therapy is around $150,000 to $250,000, which is very expensive, especially for countries without public insurance. Therefore, the high cost of checkpoint inhibitor cancer treatment is expected to limit the checkpoint inhibitor market.

Major companies in the checkpoint inhibitor market are forming partnerships or collaborations for the development of advanced technologies such as bifunctional fusion proteins or Y-trap. Most patients with cancer do not respond to immune checkpoint inhibitors. To make immunotherapies more effective, a group of researchers has developed the bifunctional fusion protein or Y-trap. This drug is created by fusing a receptor for a protein called TGF-beta that targets checkpoint proteins such as PD-L1 or CTLA-4. Y- Trap targets both a checkpoint inhibitor and TGF-beta and gives a more effective way to block the immune suppression and destroys the cancer cells. Merck, a prominent science and technology group, and GSK, a research-based global healthcare company, have announced that they have entered into a global strategic partnership to jointly create and market M7824 (bintrafusp alfa). M7824 is an investigational bi-functional fusion protein immunotherapy that is currently in clinical research, including possible registration trials, for various difficult-to-treat cancers. This includes a Phase II study to investigate M7824 compared to pembrolizumab as a first-line treatment in patients with PD-L1 expressing advanced non-small cell lung cancer (NSCLC). In another instance, in June 2020, Targovax, a Norway-based biotechnology company that develops immune activators for targeting solid tumors, entered into a collaboration with Leidos’ Explorations in Global Health (ExGloH) division for evaluating the potential of using ONCOS, a Targovax's clinical programme of oncolytic adenoviruses, as a vector to encode Microtide™ checkpoint inhibitor peptides.

In June 2020, Targovax, a Norway-based biotechnology company, entered into a collaboration with the Explorations in Global Health (ExGloH) division of Leidos to evaluate the potential of using ONCOS, a Targovax's clinical programme of oncolytic adenoviruses, as a vector to encode microtide checkpoint inhibitor peptides. The Explorations in Global Health (ExGloH) division of Leidos has created a specific, proprietary portfolio of microbially-derived peptides called MicrotideTM that act as immune checkpoint inhibitors. Leidos is a US-based company that deals with defense, aviation, information technology, and biomedical research.

North America is the largest region in the checkpoint inhibitors market in 2022. The Middle East is expected to be the fastest growing region in the global checkpoint inhibitors market share during the forecast period. The regions covered in the checkpoint inhibitors market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

The countries covered in the checkpoint inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA.

The checkpoint inhibitors market consists of sales of atezolizumab, avelumab, and durvalumab. Values in this market are "factory gate values," that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products.

The checkpoint inhibitors market research report is one of a series of new reports from The Business Research Company that provides checkpoint inhibitors market statistics, including checkpoint inhibitors industry global market size, regional shares, competitors with a checkpoint inhibitors market share, detailed checkpoint inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the checkpoint inhibitors industry. This checkpoint inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

    Table Of Contents

    1. Executive Summary

    2. Checkpoint Inhibitors Market Characteristics

    3. Checkpoint Inhibitors Market Trends And Strategies

    4. Checkpoint Inhibitors Market – Macro Economic Scenario

    4.1 COVID-19 Impact On Checkpoint Inhibitors Market

    4.2 Ukraine-Russia War Impact On Checkpoint Inhibitors Market

    4.3 Impact Of High Inflation On Checkpoint Inhibitors Market

    5. Checkpoint Inhibitors Market Size And Growth

    5.1. Global Checkpoint Inhibitors Historic Market, 2017-2022, $ Billion

    5.1.1. Drivers Of The Market

    5.1.2. Restraints On The Market

    5.2. Global Checkpoint Inhibitors Forecast Market, 2022-2027F, 2032F, $ Billion

    5.2.1. Drivers Of The Market

    5.2.2. Restraints On the Market

    6. Checkpoint Inhibitors Market Segmentation

    6.1. Global Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    PD-1 Inhibitors

    PD-L1 Inhibitors

    CTLA-4

    Chimeric Antigen Receptor T-cell

    Other Drugs

    6.2. Global Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    Lung Cancer

    Renal Cancer

    Blood Cancer

    Bladder Cancer

    Melanoma

    Other Applications

    6.3. Global Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    Hospitals Pharmacies

    Retail Pharmacies

    Online Pharmacies

    7. Checkpoint Inhibitors Market Regional And Country Analysis

    7.1. Global Checkpoint Inhibitors Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    7.2. Global Checkpoint Inhibitors Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    8. Asia-Pacific Checkpoint Inhibitors Market

    8.1. Asia-Pacific Checkpoint Inhibitors Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    8.3. Asia-Pacific Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    9. China Checkpoint Inhibitors Market

    9.1. China Checkpoint Inhibitors Market Overview

    9.2. China Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

    9.3. China Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

    10. India Checkpoint Inhibitors Market

    10.1. India Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    10.2. India Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    11. Japan Checkpoint Inhibitors Market

    11.1. Japan Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    11.2. Japan Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    12. Australia Checkpoint Inhibitors Market

    12.1. Australia Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    12.2. Australia Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    13. Indonesia Checkpoint Inhibitors Market

    13.1. Indonesia Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    13.2. Indonesia Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    14. South Korea Checkpoint Inhibitors Market

    14.1. South Korea Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    14.2. South Korea Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    15. Western Europe Checkpoint Inhibitors Market

    15.1. Western Europe Checkpoint Inhibitors Market Overview

    15.2. Western Europe Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    15.3. Western Europe Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    16. UK Checkpoint Inhibitors Market

    16.1. UK Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    16.2. UK Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    17. Germany Checkpoint Inhibitors Market

    17.1. Germany Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    17.2. Germany Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    18. France Checkpoint Inhibitors Market

    18.4. France Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    18.5. France Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    19. Eastern Europe Checkpoint Inhibitors Market

    19.1. Eastern Europe Checkpoint Inhibitors Market Overview

    19.2. Eastern Europe Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    19.3. Eastern Europe Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    20. Russia Checkpoint Inhibitors Market

    20.1. Russia Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    20.2. Russia Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    21. North America Checkpoint Inhibitors Market

    21.1. North America Checkpoint Inhibitors Market Overview

    21.2. North America Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    21.3. North America Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    22. USA Checkpoint Inhibitors Market

    22.1. USA Checkpoint Inhibitors Market Overview

    22.2. USA Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    22.3. USA Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    23. South America Checkpoint Inhibitors Market

    23.1. South America Checkpoint Inhibitors Market Overview

    23.2. South America Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    23.3. South America Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    24. Brazil Checkpoint Inhibitors Market

    24.1. Brazil Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    24.2. Brazil Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    25. Middle East Checkpoint Inhibitors Market

    25.1. Middle East Checkpoint Inhibitors Market Overview

    25.2. Middle East Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    25.3. Middle East Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    26. Africa Checkpoint Inhibitors Market

    26.1. Africa Checkpoint Inhibitors Market Overview

    26.2. Africa Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    26.3. Africa Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    27. Checkpoint Inhibitors Market Competitive Landscape And Company Profiles

    27.1. Checkpoint Inhibitors Market Competitive Landscape

    27.2. Checkpoint Inhibitors Market Company Profiles

    27.2.1. AstraZeneca PLC

    27.2.1.1. Overview

    27.2.1.2. Products and Services

    27.2.1.3. Strategy

    27.2.1.4. Financial Performance

    27.2.2. Bristol-Myers Squibb Company

    27.2.2.1. Overview

    27.2.2.2. Products and Services

    27.2.2.3. Strategy

    27.2.2.4. Financial Performance

    27.2.3. Merck & Co., Inc.

    27.2.3.1. Overview

    27.2.3.2. Products and Services

    27.2.3.3. Strategy

    27.2.3.4. Financial Performance

    27.2.4. Roche Holding AG

    27.2.4.1. Overview

    27.2.4.2. Products and Services

    27.2.4.3. Strategy

    27.2.4.4. Financial Performance

    27.2.5. Pfizer

    27.2.5.1. Overview

    27.2.5.2. Products and Services

    27.2.5.3. Strategy

    27.2.5.4. Financial Performance

    28. Checkpoint Inhibitors Pipeline Analysis

    29. Key Mergers And Acquisitions In The Checkpoint Inhibitors Market

    30. Checkpoint Inhibitors Market Future Outlook and Potential Analysis

    31. Appendix

    31.1. Abbreviations

    31.2. Currencies

    31.3. Historic And Forecast Inflation Rates

    31.4. Research Inquiries

    31.5. The Business Research Company

    31.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2017-2022, $ Billion
  • Table 2: Global Forecast Market Growth, 2022-2027F, 2032F, $ Billion
  • Table 3: Global Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 4: Global Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 5: Global Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 6: Global Checkpoint Inhibitors Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 7: Global Checkpoint Inhibitors Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 8: Asia-Pacific, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 9: Asia-Pacific, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 10: China, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 11: China, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 12: India, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 13: India, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 14: Japan, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 15: Japan, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 16: Australia, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 17: Australia, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 18: Indonesia, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 19: Indonesia, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 20: South Korea, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 21: South Korea, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 22: Western Europe, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 23: Western Europe, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 24: UK, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 25: UK, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 26: Germany, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 27: Germany, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 28: France, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 29: France, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 30: Eastern Europe, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 31: Eastern Europe, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 32: Russia, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 33: Russia, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 34: North America, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 35: North America, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 36: USA, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 37: USA, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 38: South America, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 39: South America, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 40: Brazil, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 41: Brazil, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 42: Middle East, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 43: Middle East, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 44: Africa, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 45: Africa, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 46: AstraZeneca PLC Financial Performance
  • Table 47: Bristol-Myers Squibb Company Financial Performance
  • Table 48: Merck & Co., Inc. Financial Performance
  • Table 49: Roche Holding AG Financial Performance
  • Table 50: Pfizer Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2017-2022, $ Billion
  • Figure 2: Global Forecast Market Growth, 2022-2027F, 2032F, $ Billion
  • Figure 3: Global Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 4: Global Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 5: Global Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 6: Global Checkpoint Inhibitors Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 7: Global Checkpoint Inhibitors Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 8: Asia-Pacific, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 9: Asia-Pacific, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 10: China, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 11: China, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 12: India, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 13: India, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 14: Japan, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 15: Japan, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 16: Australia, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 17: Australia, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 18: Indonesia, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 19: Indonesia, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 20: South Korea, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 21: South Korea, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 22: Western Europe, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 23: Western Europe, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 24: UK, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 25: UK, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 26: Germany, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 27: Germany, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 28: France, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 29: France, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 30: Eastern Europe, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 31: Eastern Europe, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 32: Russia, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 33: Russia, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 34: North America, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 35: North America, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 36: USA, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 37: USA, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 38: South America, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 39: South America, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 40: Brazil, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 41: Brazil, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 42: Middle East, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 43: Middle East, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 44: Africa, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 45: Africa, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 46: AstraZeneca PLC Financial Performance
  • Figure 47: Bristol-Myers Squibb Company Financial Performance
  • Figure 48: Merck & Co., Inc. Financial Performance
  • Figure 49: Roche Holding AG Financial Performance
  • Figure 50: Pfizer Financial Performance
View Report
View Report
View Report
View Report
View Report
View Report
View Report
View Report